Resverlogix news released about CANTOS back in August 2017 at ESC. 

Back in 2017, it was reported that CANTOS (Canakinumab) elicited a 3-point MACE RRR of 7%, 15% and 14% for the 50 mg, 150 mg and 300 mg doses, respectively. At a median follow-up of 3.7 years, the events per 100 patient years were 4.50, 4.11, 3.86 and 3.90 for placebo, 50 mg, 150 mg and 300 mg doses, respectively.  The reduced MACE was primarily due to significant reductions in heart attacks with non-significant trends for reduced CV death and stroke.

http://www.nejm.org/doi/full/10.1056/NEJMoa1707914

The new data presented last weekend at ACC 2018 reported pre-specified secondary endpoints:

1) One prespecified secondary endpoint was the incidence of new-onset diabetes in patients with prediabetes at baseline. Despite canakinumab having similar efficacy in preventing major cardiovascular events in patients with and without diabetes at trial entry, canakinumab had no effect vs. placebo on prevention of new-onset diabetes in patients with prediabetes at baseline. This was also seen when all doses of canakinumab were combined.

2) The other new CANTOS analysis at ACC 2018 was to determine efficacy of canakinumab in pateints with moderate CKD, who are at very high CVD risk. They found that canakinumab elicited an 18% RRR in patients with moderate CKD (7.89 vs. 6.46 events per 100 person years), whereas it elicited a 14% RRR (4.55 vs. 3.92 events per 100 person years) in patients with normal kidney function.

This all paints a great picture for the prospects of apabetalone, with its effects on inflammation, HDL, alkaline phosphatase/kidney function, glucose metabolism, etc. Go BETonMACE!

BDAZ